Resources
2 Results (showing 1 - 2)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.